GlassScriptPhysician profile
Kathryn E Swanson
NPI 1437216546
$4,546.30
in general payments reported to CMS, 2019-2025
21 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $706 · 2022: $1,302 · 2023: $707 · 2024: $1,253 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.35 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $663.18 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $627.32 | 2021-2025 | |
| Janssen Biotech, INC. | $618.87 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $554.82 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $549.60 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $284.46 | 2021-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $247.23 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $234.64 | 2022-2024 | Sotyktu |
| Pfizer INC. | $176.54 | 2022-2025 | |
| Genzyme Corporation | $135.08 | 2021-2024 | |
| Ucb, INC. | $104.21 | 2022-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $64.99 | 2022 | |
| Sun Pharmaceutical Industries INC. | $56.14 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.67 | 2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $39.34 | 2024 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $34.53 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Incyte Corporation | $26.62 | 2022 | |
| Merz North America, INC. | $24.80 | 2024 | |
| Dermavant Sciences, INC. | $24.45 | 2023 | Vtama |
| Fresenius Kabi USA, LLC | $22.56 | 2024 | Idacio |
| Paratek Pharmaceuticals, INC. | $15.25 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.